Skip to main content

Deep eutectic solvents: An innovative green approach for Solubility enhancement of poorly water-soluble drugs

Project/agreement No.
RSU-ZG-2024/1-0033
Project funding
75 000.00 EUR, project No. 5.2.1.1.i.0/2/24/I/CFLA/005 “RSU Internal and RSU with LASE External Consolidation” funded by the European Union Recovery and Resilience Facility and the budget of the Republic of Latvia
Project manager
Project realization
01.04.2025. - 31.03.2026.

Aim

This project's overall goal is to create innovative formulation approaches that will help improve the solubility of poorly water-s;oluble drugs, simultaneously reduce drug dose and lessen the environmental impact of the pharmaceutical sector by using DESs as innovative green solvents.

Description

This grant aims to create new knowledge for developing innovative deep eutectic solvents to improve the solubility of poorly soluble drugs and to simultaneously reduce drug doses and lessen the environmental impact of the pharmaceutical sector by using DESs as innovative green solvents. Key Grant Elements: Use of innovative combinations of in silico methods, based on Hansen solubility parameters and calculation of thermodynamic properties by quantum mechanical data for optimization of the results and to minimize experimental expenditure; Formation of DES by mixing DES components at a specified hydrogen bond acceptor (HBA) to hydrogen bond donor (HBD) molar ratio; Evaluating physicochemical properties of the obtained DESs to determine their suitability for further pharmaceutical applications; Solubility studies involving a drug + water + DES and surfactant+ DES combinations; Evaluation of suitability of obtained DESs for solubility enhancement of poorly water-soluble drugs (model compounds: ibuprofen,naproxen and apigenin); Assessment of widening of potential application of DESs in other priority pharmaceutical directions in accordance with goals of RSU and Lead Researcher group, preliminary experiments of ex vivo drug permeability testing across gastrointestinal membranes. This grant shows both a challenge and a significant opportunity for DESs potential application as a green innovative alternative in the pharmaceutical sector.